TABLE III. Frequencies of human leukocyte antigen (HLA) class I ligands in Zika virus (ZIKV) patients and controls.
| Patients (N = 139) | Controls (N = 170) | ||||
| HLA CLASS I ligands | n | Frequency (%) | n | Frequency (%) | p-value |
| A*03 | 26 | 18.7 | 29 | 17.1 | 0.8205 |
| A*11 | 19 | 13.7 | 16 | 9.4 | 0.3201 |
| A*03 and/or A*11 | 43 | 30.9 | 43 | 25.3 | 0.3305 |
| Bw4 | 112 | 80.6 | 142 | 83.5 | 0.5990 |
| Bw4/Bw4 | 46 | 33.1 | 51 | 30.0 | 0.6457 |
| Bw4- 80Ile | 84 | 60.4 | 119 | 70.0 | 0.1006 |
| Bw4-80Ile/ Bw4-80Ile | 27 | 19.4 | 32 | 18.8 | 0.9906 |
| Bw4-80Thr | 43 | 30.9 | 50 | 29.4 | 0.8683 |
| Bw4-80Thr/80Thr | 5 | 3.6 | 2 | 1.2 | 0.2999 |
| C*04 | 47 | 33.8 | 51 | 30.0 | 0.5528 |
| C1 | 110 | 79.1 | 134 | 78.8 | 0.9417 |
| C2 | 95 | 68.3 | 117 | 68.8 | 0.9736 |
| C1/C2 | 66 | 47.5 | 81 | 47.6 | 0.9318 |
| C1/C1 | 44 | 31.7 | 53 | 31.2 | 0.9736 |
| C2/C2 | 29 | 20.9 | 36 | 21.2 | 0.9417 |
n: number of individuals; ns: non-significant results; #The same individual could express more than one pair of HLA ligands. Bw4: HLA-A*23, A*24, A*25, A*32, B*13, B*27, B*37, B*38, B*44, B*49, B*51, B*52, B*53, B*57, B*58; Bw4-80Ile: HLA-A*23, *24, *25, *32, *15:17, *27:02, *38:01, *49:01, *51, *52:01, *53:01, *57, *58; Bw4-80Thr: HLA-B*13, *27:05, *37:01, *44; Group C1: HLA-C*01, 03, *07, *08, *12, *14, *16; Group C2: HLA-C*02, *04, *05, *06, *15, *17, *18.